Kailera Therapeutics (KLRA) director awarded 38,300 stock options at $16 strike price

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. director Frank Clyburn received a grant of stock options on April 16, 2026. The award covers 38,300 options to buy common stock at an exercise price of $16.00 per share, all held as direct ownership.

Following this grant, Clyburn holds 38,300 stock options. According to the terms, the options vest and become exercisable for 100% of the underlying shares on April 16, 2027, provided he continues to serve the company through that vesting date. The options are scheduled to expire on April 16, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Clyburn Frank

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,300	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,300 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 38,300 options Exercise price: $16.00 per share Underlying shares: 38,300 shares +3 more

6 metrics

Options granted 38,300 options Stock option grant to director on April 16, 2026

Exercise price $16.00 per share Strike price for the 38,300 stock options

Underlying shares 38,300 shares Common stock underlying the granted options

Post-grant derivative holdings 38,300 options Total stock options held after transaction

Vesting date April 16, 2027 Date when 100% of options vest, subject to service

Expiration date April 16, 2036 Scheduled expiration of the stock options

Key Terms

Stock Option (right to buy), exercise price, vesting, underlying shares, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "16.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options vest and become exercisable as to 100% of the underlying shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying shares financial

"100% of the underlying shares on April 16, 2027"

expiration date financial

"expiration_date: "2036-04-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clyburn Frank

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	04/16/2026		A		38,300		(1)	04/16/2036	Common Stock	38,300	$0	38,300	D

Explanation of Responses:

1. The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.

	/s/ John Mei, Attorney-in-fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kailera Therapeutics (KLRA) report for Frank Clyburn?

Kailera Therapeutics reported that director Frank Clyburn received a grant of 38,300 stock options. These options give him the right to buy common shares at $16.00 per share, subject to vesting and future exercise conditions set by the company.

How many Kailera Therapeutics (KLRA) stock options were granted to Frank Clyburn?

Frank Clyburn was granted 38,300 stock options. Each option relates to one share of Kailera Therapeutics common stock, so the grant covers 38,300 underlying shares, all held as direct ownership after the reported transaction.

What is the exercise price and expiration date of Frank Clyburn’s KLRA stock options?

The granted stock options have an exercise price of $16.00 per share and are scheduled to expire on April 16, 2036. This means he can choose to exercise them at $16.00 any time after vesting and before that expiration date.

When do Frank Clyburn’s Kailera Therapeutics stock options vest?

The options vest and become exercisable as to 100% of the underlying 38,300 shares on April 16, 2027. Vesting is conditioned on Clyburn’s continued service with Kailera Therapeutics through that vesting date, according to the disclosed footnote terms.

Is Frank Clyburn’s KLRA option grant an open-market purchase or compensation award?

The filing classifies the transaction as a grant or award acquisition, not an open-market purchase. The options were awarded at a $16.00 exercise price and carry vesting conditions, which is typical of equity-based director or executive compensation programs.